会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • NOVEL SUBSTITUTED AZABENZOXAZOLES
    • 新型取代的AZABENZOXAZOLES
    • US20110212031A1
    • 2011-09-01
    • US13125939
    • 2009-10-21
    • Cyrille SurDavid L. Williams
    • Cyrille SurDavid L. Williams
    • A61K49/10A61P25/16A61K31/5377A61K49/00A61P25/28A61P25/18A61K31/437
    • A61K31/519A61K51/0455A61K51/0463
    • The present invention relates to novel MAO-B binding compounds and methods for measuring effects of the compounds, by measuring changes of MAO-B levels in living patients. More specifically, the present invention relates to use of the compounds of this invention as therapeutic agents for inhibition of MAO-B activity as well as a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study MAO-B levels in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel MAO-B binding compounds as diagnostic, as we a therapeutic, agents. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted azabenzoxazole derivatives, compositions, and therapeutic uses and processes for making such compounds.
    • 本发明涉及通过测量活体患者中MAO-B水平的变化来测量化合物的效果的新型MAO-B结合化合物和方法。 更具体地,本发明涉及本发明化合物作为抑制MAO-B活性的治疗剂的用途以及使用本发明化合物作为正电子发射断层摄影(PET)成像中的示踪物来研究MAO的方法 -B水平在体内,以允许诊断阿尔茨海默病。 因此,本发明涉及新型MAO-B结合化合物作为诊断的用途,作为治疗剂。 本发明还涉及测量阿尔茨海默病治疗剂的临床疗效的方法。 具体地,本发明涉及新的芳基或杂芳基取代的氮杂苯并恶唑衍生物,组合物,以及用于制备这些化合物的治疗用途和方法。
    • 4. 发明申请
    • NOVEL SUBSTITUTED AZABENZOXAZOLES
    • 新型取代的AZABENZOXAZOLES
    • US20110085985A1
    • 2011-04-14
    • US12995314
    • 2009-05-28
    • James C. BarrowScott HarrisonJames MulhearnCyrille SurDavid L. WilliamsScott Wolkenberg
    • James C. BarrowScott HarrisonJames MulhearnCyrille SurDavid L. WilliamsScott Wolkenberg
    • A61K31/437C07D498/04C07D519/00A61K31/5377A61K49/00A61K49/04A61K49/06A61P25/28A61P25/18
    • C07D498/04C07D519/00
    • The present invention relates to novel amyloid binding compounds of formula (I) and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET/) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted azabenzoxazole derivatives, compositions, and therapeutic uses and processes for making such compounds, or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein: X is O or S; A and Y independently are N, or CH;
    • 本发明涉及式(I)的新型淀粉样蛋白结合化合物和通过测定活体患者淀粉样斑块水平的变化来测定化合物的效果的方法。 更具体地说,本发明涉及使用本发明化合物作为正电子发射断层摄影(PET /)成像中的示踪剂来研究脑中淀粉样蛋白沉积物以允许诊断阿尔茨海默病的方法。 因此,本发明涉及新型淀粉样蛋白结合化合物作为诊断用途。 本发明还涉及测量阿尔茨海默病治疗剂的临床疗效的方法。 具体地,本发明涉及新的芳基或杂芳基取代的氮杂苯并恶唑衍生物,组合物,以及用于制备这些化合物或其药学上可接受的盐,溶剂合物或体内可水解的酯的治疗用途和方法,其中:X是O或S; A和Y独立地为N或CH;